首页> Scientific reports> PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancer.

PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Emily,Lee

第一单位： Novartis Institutes for Biomedical Research, Cambridge, MA, USA.

作者： Emily,Lee ^[1] ; Sarah,Szvetecz ^[1] ; Ryan,Polli ^[2] ; Angelo,Grauel ^[3] ; Jayson,Chen ^[4] ; Joyce,Judge ^[5] ; Smita,Jaiswal ^[5] ; Rie,Maeda ^[1] ; Stephanie,Schwartz ^[3] ; Bernd,Voedisch ^[6] ; Mateusz,Piksa ^[6] ; Chietara,Japutra ^[7] ; Lingheswar,Sadhasivam ^[7] ; Yiqin,Wang ^[7] ; Ana,Carrion ^[7] ; Sinan,Isim ^[1] ; Jinsheng,Liang ^[1] ; Thomas,Nicholson ^[1] ; Hong,Lei ^[1] ; Qing,Fang ^[1] ; Michelle,Steinkrauss ^[5] ; Dana,Walker ^[5] ; Joel,Wagner ^[1] ; Viviana,Cremasco ^[3] ; Hui Qin,Wang ^[1] ; Giorgio G,Galli ^[8] ; Brian,Granda ^[7] ; Keith,Mansfield ^[5] ; Quincey,Simmons ^[5] ; Andrew Anh,Nguyen ^[9] ; Nicole,Vincent Jordan ^[10]

作者单位： Novartis Institutes for Biomedical Research, Cambridge, MA, USA. ^[1] PKS Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA. ^[2] Immuno-Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA. ^[3] PCS Toxicology, Novartis Institutes for Biomedical Research, East Hanover, NJ, USA. ^[4] PCS Toxicology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA. ^[5] NIBR Biologics Center, Novartis Institutes for Biomedical Research, Basel, Switzerland. ^[6] NIBR Biologics Center, Novartis Institutes for Biomedical Research, Cambridge, MA, USA. ^[7] Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland. ^[8] NIBR Biologics Center, Novartis Institutes for Biomedical Research, Cambridge, MA, USA. anh.nguyen@novartis.com. ^[9] Novartis Institutes for Biomedical Research, Cambridge, MA, USA. nicole.vincentjordan@gmail.com. ^[10]